stroke and embolism trial in atrial fibrillation). J Am CollCardiol. 2013; 61 (6): 651- 658.
18. Sosa Rosado JM. Nuevos anticoagulantes orales en la prevención de fenómenos tromboembólicos en la fibrilación auricular no valvular. AnFacmed. 2013; 74 (2):139-143.
19. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M et al.Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J ThromnHaemost. 2012;18: 1979-1987.
20. Sá SPD, Rodrigues RP., Santos-AntunesJ, Gonçalves FR, Nunes JPL.Antithrombotic therapy in nonvalvular atrial fibrillation: a narrative review. Rev Port de Cardiolog. 2011 Dec; 30 (12): 905-924.
21. Harenberg J, Wehling M. Future of anticoagulant therapy. CardiovascTher. 2011 Oct;29(5):291-300.
22. Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP et al. rivaroxaban in patients transitioned from vitamin k antagonist therapy. Annals Int Med. 2013; 159: 861- 868.
23. Harris k, Mant J. V Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.Int J ClinPract. 2013; 67 (7): 647-655.
24. Baker WL, Phung OJ. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. CircCardiovascQual Outcomes. 2012 Sep 1;5(5):711-9.
25. Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. IntAngiol. 2012 Aug;31(4):330-9.
26. Christopher B. Granger, MD; Luciana V. Armaganijan, MD.Newer Oral Anticoagulants Should Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or Thromboembolism.Circulat. 2012; 125: 159-164.
27. Casey M. Ya es hora de remplazar a los dicumarínicos. RevArg de Cardiol. 2012; 80 (5): 381-386.
28. Bosch M, Llop R, LaluezaP,Villar MM. Nuevos anticoagulantes orales para la prevención del ictus en pacientes con fibrilación auricular no valvular. Med Clin (Barc). 2013;140(5):229–231.
29. Tseluĭko VI, Opolonskaia NA, Vashakidze ZS. Comparison of the therapeutic effect of the Warfarin and Rivaroksaban among the patients with not-valuate fibrillation of atrium.Georgian Med News. 2013 Jun;219:28-33.
30. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011; 32 (19): 2387-2394.
31. Patal MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl Med. 2011; 365 (10): 883- 891.
32. Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med. 2013 Jun 18; 158(12):861-868.
33. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE et al. Outcomes After Cardioversion and Atrial Fibrillation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial. J Am CollCardiol. 2013; 61 (19): 1998-2006.
34. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S et al. Safety and efficacy of adjusted dose of rivaroxaban injapanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J. 2013; 77: 632-638.
35. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S et al.Rivaroxaban vs. Warfarin in japanese patients with trial fibrillation: The J-ROCKET AF study .Circ J. 2012; 76: 2104-2111.
36. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012 Sep 15;110(6):845-851.